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Abstract: Methods of harnessing the immune system to treat cancer 
have been investigated for decades, but yielded little clinical progress. 
However, in recent years, novel drugs that allow immune recognition 
and destruction of tumor cells are emerging as potent cancer therapies. 
Building upon previous immunotherapy strategies that included thera-
peutic vaccines, recombinant cytokines, and other immunostimulatory 
agents, newer immunotherapy agents targeting immune checkpoints 
including programmed cell death 1, programmed cell death ligand-1, 
and cytotoxic T-lymphocyte-associated protein 4, among others, have 
garnered substantial enthusiasm after demonstrating clinical activity in 
a broad spectrum of tumor types. Trials evaluating immune checkpoint 
inhibitors in metastatic non–small-cell lung cancer (NSCLC) demon-
strate robust and durable responses in a subset of patients. However, 
with overall response rates less than 20%, combinatorial strategies 
that extend the beneﬁt of these agents to more patients are desirable. 
The integration of radiotherapy with immunotherapy is a conceptu-
ally promising strategy, as radiotherapy has potent immunomodulatory 
effects and may contribute not only to local control but may also aug-
ment systemic antitumor immune response. Preclinical data and case 
reports suggest the potential for robust clinical responses in metastatic 
NSCLC patients using this strategy, but prospective clinical trials eval-
uating the integration of radiation and immunotherapy are limited. The 
use of immunotherapy in nonmetastatic settings is also intriguing but 
understudied. We review the potential clinical settings of interest for 
the partnering of immunotherapy and radiation in NSCLC, including 
early stage, locally advanced, and metastatic disease, and review com-
pleted, accruing, and developing clinical trials.
Key Words: Non–small-cell lung cancer, Immunotherapy, 
Radiotherapy.
(J Thorac Oncol. 2015;10: 1685–1693)
Lung cancer has traditionally been characterized as insen-sitive to immune strategies. The ﬁrst randomized trials 
to evaluate immunotherapy date back to the 1970s with the 
instillation of adjuvant intrapleural BCG.1,2 Although BCG 
was ineffective, the pursuit of an immune agent to treat 
lung cancer continued. Phase III trials evaluating interferon 
and a variety of vaccines, however, were  unsuccessful.3,4 
Meanwhile, dramatic advances in our understanding of the 
molecular mechanisms of tumor immunology, now known 
as the cancer-immunity cycle, have allowed for the devel-
opment of new drugs and improved vaccines and cellular 
therapies, reigniting enthusiasm for immunotherapy of lung 
cancer.5 Most exciting is the new class of agents called 
immune checkpoint inhibitors. Checkpoint inhibitors tar-
geting programmed cell death 1 (PD-1), programmed cell 
death ligand-1 (PD-L1), cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4), and others have demonstrated clini-
cal efﬁcacy in a broad spectrum of tumor types, with pro-
nounced and durable remissions in a subset of patients. In 
lung cancer, PD-1 and PD-L1 inhibitors as monotherapy for 
metastatic non–small-cell lung cancer (NSCLC) have shown 
response rates of 15% to 20%, with typically dramatic and 
durable results in both nonsquamous and squamous histolo-
gies.6–8 A recently published phase III trial comparing the 
anti-PD-1 monoclonal antibody nivolumab to docetaxel 
as second-line treatment for advanced squamous NSCLC 
demonstrated superior median survival of 9.2 months (95% 
conﬁdence interval [CI]: 7.3–13.3) with nivolumab as com-
pared with 6.0 months (95% CI: 5.1–7.3) with docetaxel,9 
and a parallel study identiﬁed superior median survival of 
12.2 months (95% CI: 9.7, 15.0) for nivolumab versus 9.4 
months (95% CI: 8.0, 10.7) with docetaxel for nonsqua-
mous histology (hazard ratio = 0.73; 96% CI: 0.59, 0.89; 
p = 0.00155).10 Nivolumab was recently FDA approved for 
the second-line treatment of advanced stage patients with 
squamous histology.11
There is substantial interest in extending the beneﬁt 
of immune checkpoint inhibitors to a greater proportion to 
patients. Efforts are underway to develop combined modal-
ity strategies, including dual immunotherapies, integration 
of chemotherapy and targeted therapies, and combination 
with radiotherapy. Radiotherapy is a particularly appeal-
ing partner therapy, offering the beneﬁt of a generally 
nonoverlapping toxicity proﬁle, with both preclinical and 
early clinical data suggesting potential potent immunos-
timulatory effects. Radiotherapy induces multiple immu-
nomodulatory changes that can potentially influence the 
effectiveness of immunotherapy including tumor vascu-
lature normalization,12 improved T-cell extravasation and 
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homing to tumors,12 destruction of immunosuppressive 
stromal cells,13 induction of immunogenic tumor cell death 
via high mobility group protein B1 release,14 or exposure 
of calreticulin on the cell surface,15 among others (Table 1, 
Fig. 1). Clinical support for an interaction between radio-
therapy and the immune response is demonstrated by the 
abscopal (ab-scopus, away from the target) effect, in which 
a systemic tumor response is observed after local radia-
tion.24 Although once thought to be an infrequent event, 
increasing reports of an abscopal effect with the combina-
tion of immune checkpoint inhibitors and radiation have 
renewed our interest in this phenomenon and justify the 
evaluation of immunoradiotherapy strategies.25
Clinical studies evaluating immunotherapy and radia-
tion for NSCLC have focused on metastatic disease. However, 
other settings, including early stage and locally advanced dis-
ease, are also intriguing. The effects of immunotherapy may 
be best suited to eradication of micrometastases, suggesting 
neoadjuvant, concurrent, or adjuvant immunotherapy strate-
gies in the localized setting should be further explored. We 
review a representative sample of completed, ongoing, and 
developing clinical trials evaluating the combination of radio-
therapy and immunotherapy for NSCLC, and suggest areas 
for future investigation.
IMMUNOTHERAPY AND RADIATION IN 
METASTATIC NSCLC
Rationale
Early combinatorial strategies for radiotherapy and immu-
notherapy in NSCLC have logically focused on patients with 
metastatic disease, a patient population with a dismal median 
survival of 10 to 12 months and few efﬁcacious treatment 
strategies beyond ﬁrst-line chemotherapy.26 Important ques-
tions include not only the efﬁcacy of radiation–immunotherapy 
combinations, patient selection, and choice of immunotherapy 
agent(s), but also the optimal sequencing, radiotherapy dose/
fractionation, disease burden at treatment, and impact of poten-
tially immunosuppressive prior therapies. Relatively few studies 
have been completed, but substantial enthusiasm for these agents 
has led to a number of accruing and developing clinical trials. 
Many currently accruing trials combine immunotherapy agents 
with stereotactic body radiotherapy (SBRT), a precise technique 
that allows delivery of high radiation doses over one to ﬁve 
fractions. The optimal dose and fractionation to best augment 
the antitumor immune response, however, is unclear. A study 
combining a toll-like receptor 7 agonist and local radiation in a 
murine lymphoma model found that 2 Gy ×5 fractions resulted 
in greater tumor response than the toll-like receptor 7 agonist and 
a single 10 Gy fraction.27 Similarly, a study using a breast cancer 
murine model found that anti-CTLA-4 therapy combined with 
fractionated radiation (8 Gy ×3 or 6 Gy ×5) resulted in abscopal 
tumor responses while the same immunotherapy combined with 
20 Gy ×1 did not generate a systemic response.28 By contrast, a 
study using a murine melanoma model found that a single dose 
of 20 Gy better promotes priming of antigen-speciﬁc cells than 4 
Gy ×5, and that 12 Gy ×2 combined with intratumoral injections 
of a T cell therapy resulted in prolonged survival and prevented 
metastases.29 Other work in murine melanoma models suggests 
a moderate, hypofractionated regimen using 7.5 Gy fractions 
may optimize tumor control, antitumor immunity, and minimize 
the contribution of regulatory T cells.30 Similar studies speciﬁc 
to lung cancer models are lacking.
Completed and Currently Accruing 
Clinical Studies in Metastatic Disease
Trials combining immune checkpoint inhibitors with 
radiotherapy are ongoing or planned as shown in Table 2. After 
noting a durable complete systemic response in a NSCLC 
patient treated with ipilimumab plus SBRT to a liver lesion, 
investigators at New York University have activated a phase 
I/II study evaluating ipilimumab delivered at 3 mg/kg IV 
combined with SBRT to 30 Gy over ﬁve fractions to a single 
metastasis for stage IV NSCLC31,32 (NCT02221739). SBRT 
and ipilimumab begin within a 24-hour interval, and ipili-
mumab is repeated every 21 days for up to four cycles. The 
primary outcome measure is tumor response by the immune-
related response evaluation criteria in solid tumors33 outside 
the radiation ﬁeld.
A second accruing study evaluates radiotherapy and 
ipilimumab for metastatic solid tumors, including NSCLC. 
Investigators at the MD Anderson Cancer Center have acti-
vated a phase I/II trial enrolling patients with metastatic solid 
TABLE 1. Mechanisms of Radiation-Induced Immune 
Modulation
Tumor debulking and releasing tumor 
antigens
Not systemically immunosuppressive
Up-regulation of immunogenic cell surface  
 markers
  ICAM-1 Chakraborty et al.16
  MHC-1 Formenti et al.17
  Fas Chakraborty et al.16
Secretion of danger signals and cytokines
  IFN-g Lugade et al.18
  TNFa Formenti et al.17
  IL-1b Formenti et al.17
Induction of immunogenic cell death
  Calreticulin Obeid et al.19
  HMGB1 Apetoh et al.14
Increased homing of immune cells to tumors
  Normalization of tumor vasculature Ganss et al.20
  Secretion of chemo-attractants (cxcl16) Matsumura et al.21
  Endothelial expression of VCAM-1 Lugade et al.18
  Improved T-cell homing to tumors Klug et al.12
Improved antigen presentation by APC’s
  Irradiated tumors prime dendritic cells Strome et al.22
  Improved antigen presentation via TLR-4 Apetoh et al.14
Depletion of immunosuppressive cells Wu et al.13
Shifting TAM polarization to M1 Klug et al.12
Up-regulation of cell surface PD-L1 Dovedi et al.23
MHC-1, major histocompatibility complex 1; HMGB-1, high mobility group protein 
B1; VCAM, Vascular Cell Adhesion Protein-1; APC, Antigen-presenting cell; TLR-4, 
toll-like receptor; TAM, tumor-associated macrophage; PD-L1, programmed cell death 
ligand-1.
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tumors evaluating ipilimumab (3 mg/kg every 21 days) and 
SBRT to either a liver, lung, or adrenal lesion with a starting 
SBRT dose of 50 Gy in four fractions or 60 Gy in 10 frac-
tions34 (NCT02239900). The investigators include separate 
arms to evaluate concurrent or sequential SBRT delivery. 
The safety, efﬁcacy, toxicity proﬁle, and the maximally toler-
ated dose for SBRT are the primary outcome measures, with 
immune-related response evaluation criteria in solid tumors 
response a secondary measure.
A currently accruing study designed to explore the 
immunomodulatory effects of radiotherapy with check-
point blockade at Thomas Jefferson University combines the 
PD-1 inhibitor pembrolizumab with single or multi-fraction 
radiotherapy to a metastatic site for patients with metastatic 
NSCLC, melanoma, head and neck cancer, or renal cell car-
cinoma35 (NCT02318771). Radiotherapy is 8 Gy in one frac-
tion or 20 Gy over ﬁve fractions, and patients are stratiﬁed 
into concurrent (radiation and pembrolizumab initiated on the 
same day) or sequential (radiation delivered ﬁrst, with a post-
radiation biopsy, followed by pembrolizumab 10 days later). 
Pembrolizumab is continued over 21 day cycles until dis-
ease progression or unacceptable toxicity. Change in PD-L1 
expression is the primary outcome measure, with secondary 
measures of response rate, toxicity, progression-free survival, 
and biomarker expression.
A registered trial currently pending activation at the 
University of Pennsylvania will evaluate hypofractionated 
radiotherapy with the PD-1 inhibitor pembrolizumab in mela-
noma and NSCLC patients who previously failed anti-PD-1 
or PD-L1 monotherapy, or other metastatic solid tumors who 
failed at least ﬁrst-line systemic therapy36 (NCT02303990). 
Details on timing of therapy and radiation fractionation are 
not yet available. However, the choice to include a cohort of 
NSCLC patients previously refractory to anti-PD-1 or PD-L1 
therapy highlights the largely unexplored potential for radio-
therapy to induce responses in tumors initially unresponsive 
to checkpoint inhibition. Retrospective clinical series evaluat-
ing melanoma patients suggest that following disease progres-
sion on ipilimumab, local radiotherapy generates an abscopal 
effect.37 The use of radiotherapy speciﬁcally to generate or 
regenerate a response following failure of checkpoint inhibi-
tion in NSCLC is essentially unexplored, and this trial should 
provide valuable information on the viability of this strategy.
Our group is preparing to activate a study exploring the 
impact of timing of SBRT in relation to immunotherapy. We 
will enroll patients with metastatic NSCLC who have pro-
gressed on at least one line of prior systemic therapy to receive 
the PD-L1 inhibitor MPDL3280A until tumor progression or 
intolerable toxicity and SBRT to a single metastatic site. The 
trial has three arms exploring different timing approaches: 
sequential (SBRT followed by MPDL3280A), concurrent 
treatment, or priming (two cycles of MPDL3280A then deliv-
ery of SBRT with cycle 3).38 Unpublished preclinical data 
from our institution suggests that the sequencing of immu-
notherapy and SBRT can markedly affect response rates. This 
ﬁnding has recently been corroborated by other groups.16 We 
expect the results of this trial to provide valuable insight into 
the optimal sequencing strategy for future studies.
A small prospective trial testing the combination of a 
unique immunocytokine plus radiation for metastatic NSCLC 
was recently reported. Van Den Huevel et al. completed a 
Phase Ib study enrolling 13 metastatic and nonprogressing 
NSCLC patients following ﬁrst-line chemotherapy. Local radi-
ation was delivered to a single pulmonary nodule to 20 Gy in 
ﬁve fractions delivered day 7 to day 3. Starting day 1, patients 
received a human antibody speciﬁc for necrotic DNA fused 
to a genetically modiﬁed human interleukin 2 (IL-2; NHS-
ILS) that selectively activates the high-afﬁnity IL-2 receptor. 
fIGURE 1. Radiotherapy induces 
multiple immunomodulatory changes 
that can potentially influence the 
effectiveness of immunotherapy. 
Shown above from left to right and in 
Table 1: radiation may lead to direct 
tumor cell killing; upregulation of 
immunogenic cell surface markers, 
such as MHC-1; secretion of danger 
signals and cytokines, such as TNF-
alpha; induction of immunogenic cell 
death via calreticulin and HMGB-1, 
among others; improved homing of 
immune cells, such as cytotoxic T lym-
phocytes to tumor; improved antigen 
presentation by mechanism including 
priming of dendritic cells; a shift in 
TAM from the M2 to M1 phenotype; 
and upregulation of cell surface PD-L1, 
among others. MHC-1, major histo-
compatibility complex 1; HMGB-1, 
high mobility group protein B1; TAM, 
tumor-associated macrophage; PD-L1, 
programmed cell death ligand-1.
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Patients received escalating doses of 0.15, 0.30, or 0.45 mg/kg 
daily by IV infusion for three consecutive days every 21 days 
until disease progression or intolerable side effects. The maxi-
mally tolerated dose was not reached; two of 13 patients had 
long-term disease control. Side effects were mild, including 
fatigue, anorexia, rash, and thyroid dysfunction.39 No other 
completed, prospective trials have been published.
future Directions in Metastatic NSCLC
While currently accruing trials exploring radiation–
immunotherapy combinations should provide preliminary 
evidence for the efﬁcacy of this approach, key details address-
ing the radiation component are not deﬁned, including tim-
ing, fractionation, selection of a radiation target, and impact 
of disease burden. Crucial questions in patient selection also 
include baseline patient immune function and the impact of 
short- or long-term of potentially immunosuppressive medica-
tions, such as corticosteroids. Biomarkers to predict response 
are also urgently needed.
Two subsets of patients with metastatic disease deserve 
special mention (1) those with limited burden or oligometa-
static disease and (2) patients with brain metastasis. The 
potential to eradicate limited burden macroscopic disease 
via SBRT with concurrent or sequential immunotherapy tar-
geting micrometastatic disease is mechanistically promising 
but unexplored. NSCLC patients with brain metastases are 
known to have a poorer prognosis, with a median survival 
of approximately 7 months with standard therapies includ-
ing whole brain radiotherapy or stereotactic radiosurgery.40 
Treatment options for radiotherapy failures are dismal. 
Systemic therapy, including immune checkpoint inhibitors, 
has been reported to temporarily shrink brain metastases.41 
A small study of 10 patients with untreated or progressing 
brain metastasis after radiation received pembrolizumab. 
Four of nine evaluable patients had an objective response in 
the brain, and no grade three to four adverse CNS events were 
observed.42 In the setting of melanoma brain metastases, ipili-
mumab has demonstrated a 16% intracranial response rate.43 
Interestingly, extracranial responses have been described in 
patients previously refractory to ipilimumab treated with 
radiotherapy for brain metastases. Grimaldi et al. report 21 
patients with metastatic melanoma who progressed through 
treatment with ipilimumab and subsequently required pal-
liative radiotherapy at a median of 5 months (range: 3.4–8.0 
months) after initiation of ipilimumab, including 13 patients 
with brain metastases. Abscopal responses outside the radia-
tion ﬁeld were noted in 11 patients (52%), including seven of 
13 (54%) treated for brain metastases (four with whole brain 
radiation and three with stereotactic radiosurgery).37 These 
observations suggest that radiotherapy–immunotherapy 
strategies should be investigated for the treatment of brain 
metastases, and there is an ongoing clinical trial examining 
combining radiotherapy and ipilimumab for the treatment of 
brain metastases.44
Use of dual checkpoint blockade with radiotherapy 
is also promising in preclinical models, and may over-
come resistance to single-agent combinatorial strategies. 
Researchers at the University of Pennsylvania report data 
combining CTLA-4 blockade, PD-L1 blockade, and radio-
therapy in a murine melanoma model. The addition of 
PD-L1 blockade to tumors previously resistant to CTLA-4 
blockade and radiotherapy improved responses, and for 
treatment-naïve tumors complete responses to triple therapy 
were an impressive 80%. Mechanistic correlates demon-
strated complementary mechanisms of immune modulation, 
including decreased T regulator cells secondary to CTLA-4 
blockade, reinvigoration of exhausted CD8 tumor inﬁltrat-
ing lymphocytes via PD-L1 blockade, and diversiﬁcation of 
the T cell receptor repitoire of the tumor inﬁltrating lym-
phocytes induced by radiotherapy.45 However, dual blockade 
with radiotherapy has not yet been reported in human clinical 
trials nor in lung cancer preclinical models.
In aggregate, future clinical trials evaluating radio-
therapy–immunotherapy combinations should further clarify 
the optimal selection and sequencing of treatment, choice of 
the radiotherapy target(s) and dose schema, and illuminate 
the utility of more aggressive eradication of oligometastatic 
deposits.
TABLE 2. Clinical Trials Combining Immunotherapy and Radiation for Metastatic NSCLC
Institution/Group Phase Eligibility Radiotherapy Immunotherapy
Completed
  Netherlands Cancer Institute Ib Metastatic NSCLC; disease control with ﬁrst-line 
palliative chemotherapy
5 Gy ×4 Dose-escalated NHS-IL2 on 
three consecutive days q3 
week
Accruing
  Thomas Jefferson University I Metastatic or recurrent solid tumor (NSCLC, H&N, 
RCC, skin, melanoma)
8 Gy ×1 or 4 Gy ×5 MK-3475 IV Q 21 days until 
PD or unacceptable toxicity
  University of Pennsylvania 
NCT02303990
I Metastatic melanoma or NSCLC that failed anti PD-1 
therapy
Not stated Pembrolizumab (schedule not 
stated)
  MD Anderson I/II Metastatic solid tumor with ≥1 prior therapy; lung, 
liver, or adrenal lesion amenable to SBRT
12.5 Gy ×4 or 6 Gy ×10 Dose-escalated ipilimumab × 
four cycles Q3W (starting 
dose 3 mg/kg IV)
  New York University II Metastatic NSCLC with ≥1 prior therapy; ≥2 
measurable disease sites
6 Gy ×5 Ipilimumab 3 mg/kg IV ×4 
cycles (Q3W)
NSCLC, non–small-cell lung cancer; Gy, Gray; NHS-IL2, human antibody speciﬁc for necrotic DNA fused to a genetically modiﬁed human interleukin-2.
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IMMUNOTHERAPY AND RADIATION IN 
LOCALLY ADVANCED NSCLC
Rationale
Concurrent chemoradiation (CRT) has remained the 
mainstay of therapy for locally advanced, unresectable NSCLC 
for more than two decades. Early trials demonstrated a sur-
vival beneﬁt with the addition of sequential chemotherapy to 
radiotherapy,46,47 and subsequent studies conﬁrmed a beneﬁt to 
concurrent as opposed to sequential therapy for good perfor-
mance patients.48–51 Further efforts to improve outcomes via 
radiation dose escalation,52 use of induction53,54 or consolida-
tion chemotherapy,55 or via the integration of molecular tar-
geted agents56 have been disappointing, and 5-year survival 
remains less than 30%, with distant failure the predominant 
relapse pattern.57,58 Innovative strategies to improve outcomes 
for patients with locally advanced NSCLC are desperately 
needed. Immunotherapy is a logical therapeutic addition for 
locally advanced NSCLC, as thoracic radiotherapy should 
eradicate macrometastatic disease and promote antitumor 
immunogenicity. However, the optimal approach to integrate 
immunotherapy agents into combined modality treatment 
is unclear.
Completed and Currently 
Accruing Clinical Trials
Relatively few completed prospective studies have com-
bined immunotherapy and radiotherapy for locally advanced 
NSCLC (Table 3). A phase III trial published in 1997 enrolled 
patients with resected NSCLC and included a subset of 
patients treated with both radiotherapy and immunotherapy. 
Patients were stratiﬁed based on “curative” (complete) or 
noncurative (residual nodes, metastatic disease, or positive 
margin) resection. Patients with noncurative resection were 
randomized to either standard adjuvant therapy alone, includ-
ing mediastinal radiotherapy for incomplete resections, or 
standard adjuvant therapy with the addition of IL-2 and lym-
phokine activated killer (LAK) cell adoptive immunotherapy. 
Patients with “curative” resections were randomized to no 
additional therapy versus chemoimmunotherapy with cispla-
tin, vindesine, mitomycin C, and IL-2/lymphokine activated 
killer. Patients receiving radiotherapy were not analyzed sepa-
rately, but both the “curative” and “noncurative” populations 
resulted in improved 5- and 9-year survival with the addition 
of immunotherapy.59
The most extensively studied immunotherapy agent for 
locally advanced NSCLC is the liposomal vaccine L-BLP25 
(tecemotide), a synthetic lipopeptide designed to induce a T 
cell response to the mucin 1 (MUC1) glycoprotein which is 
overexpressed and abnormally glycosylated in NSCLC and 
other solid tumors and is involved in pathways promoting 
growth, proliferation, and survival of cancer cells.60 After 
an initial phase I trial in stage IIIB/IV NSLCL patients that 
demonstrated safety and tolerability (including patients 
with prior thoracic radiation),61 Butts et al.62,63 enrolled 171 
patients with stage IIIB/IV NSCLC and stable disease or 
clinical response to standard therapy (chemotherapy for 
stage IV or thoracic CRT for stage IIIB) to a randomized 
phase IIB comparison of L-BLP25 versus best supportive 
care. A 3-week washout period was followed by enrollment 
and randomization to best supportive care or 8 weekly doses 
of L-BLP25 with a single low dose of cyclophosphamide 3 
days before cycle 1. At investigator discretion, maintenance 
L-BLP25 was delivered at 6-week intervals. Although the 
investigators did not explicitly evaluate radiotherapy/immu-
notherapy combinations, they included a subset of patients 
treated with radiotherapy. An updated analysis identiﬁed a 
signiﬁcant survival advantage in the immunotherapy arm for 
the entire population, with 3-year overall survival of 31% 
versus 17% (p = 0.035). Among the small subset of patients 
with stage IIIB NSCLC treated with CRT, the 3-year OS 
was 49% versus 27% favoring the addition of L-BLP25 (p = 
0.07) with a median survival improvement of 17.3 months. 
The authors speculate that use of radiotherapy in 85% of 
stage IIIB patients may have augmented antitumor effects 
of L-BLP25.
This phase II trial was followed by an international, 
double-blind phase III randomized trial, stimulating targeted 
antigenic response to NSCLC (START), enrolling locally 
advanced NSCLC patients. 1513 eligible patients completed 
concurrent or sequential CRT for stage IIIA/B NSCLC with 
conﬁrmed stable disease or objective response, and were 
randomized 2:1 in a double blind fashion to maintenance 
L-BLP25 versus placebo. In the planned analysis for all eli-
gible patients, no signiﬁcant difference in median survival 
was identiﬁed (25.6 versus 22.3 months; p = 0.12). In an 
unplanned subgroup analysis stratifying by use of concur-
rent versus sequential CRT, a statistically signiﬁcant survival 
beneﬁt was identiﬁed for patients treated with concur-
rent CRT (30.8 versus 20.6 months; p = 0.016) but not for 
sequential CRT (19.4 versus 24.6 months; p = 0.38).64 A trial 
in Japan similarly accrued patients with unresectable stage 
III NSCLC without progression following concurrent or 
sequential CRT to an integrating phase I/randomized phase 
II study comparing L-BLP25 with placebo.65 A planned anal-
ysis identiﬁed no beneﬁt in overall survival or any secondary 
endpoint, and as a result the development of L-BLP25 was 
discontinued prematurely, closing the INSPIRE and START2 
trials for NSCLC patients treated with concurrent CRT.66–68 
However, an ongoing Eastern Cooperative Oncology Group 
trial is evaluating the combination of L-BLP25 and bevaci-
zumab after concurrent CRT and consolidative chemother-
apy (NCT00828009).69
There is substantial interest in incorporating newer 
immunotherapy agents, particularly immune checkpoint 
inhibitors, into treatment algorithms for locally advanced dis-
ease. The currently accruing Phase III double-blind PACIFIC 
trial randomizes patients with unresectable stage IIII NSCLC 
without progression following deﬁnitive concurrent CRT 2:1 
to maintenance therapy with the PD-L1 inhibitor MEDI4736 
versus placebo for a maximum of 12 months or until progres-
sion70 (NCT02125461). Similarly, a developing trial within 
the radiation therapy oncology group foundation proposes the 
addition of nivolumab after concurrent CRT.
One trial has evaluated the use of immunotherapy with 
node positive, resectable NSCLC. Radiation therapy oncology 
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group 9909 evaluated concurrent and adjuvant delivery of 
two novel anti-idiotype cancer vaccines designed to gener-
ate an immune response against two common tumor antigens: 
carcinoembryonic antigen and human milk fat globule anti-
gen after surgical resection of stage II/IIIA NSCLC. Vaccines 
were delivered in combination with postoperative radio-
therapy, without chemotherapy. However, the trial was close 
prematurely following enrollment of 22 patients and results 
have not been reported.71 No further trials have attempted inte-
gration of immunotherapy and radiation in the trimodality or 
postoperative setting for locally advanced disease.
future Directions
While results from ongoing and developing trials should 
help clarify the role of immune checkpoint inhibitors for locally 
advanced, unresectable NSCLC, many questions remain. No 
studies have explored integration of immunotherapy as concur-
rent or neoadjuvant therapy for locally advanced disease, and 
such approaches will be complicated by the delivery of che-
motherapy. Systemic chemotherapy used for locally advanced 
disease is often immunosuppressive and may hinder tumor-
directed immune activation, although certain chemotherapies 
may induce immunogenic cell death in preclinical models,14 
potentially augmenting immune response and synergizing 
with radiation–immunotherapy combinations. It is also unclear 
whether the conventionally fractionated, larger-ﬁeld radio-
therapy used for locally advanced disease will have the immu-
nostimulatory effects of more localized, high dose SBRT, or 
may result in immunosuppression via incidental irradiation of 
adjacent bone marrow and circulating blood volume. Timing 
and patient selection will likely be crucial to realizing a beneﬁt 
in this setting. For patients unable to tolerate systemic chemo-
therapy, concurrent or sequential immunotherapy with radia-
tion should also be explored. Checkpoint inhibitors should also 
be systematically tested as part of the treatment algorithm for 
node positive, resectable disease.
IMMUNOTHERAPY AND RADIATION  
IN EARLY STAGE NSCLC
Rationale
Surgical resection remains the standard therapy for 
early stage (stage I/II) NSCLC, with systemic chemotherapy 
added for high risk or node positive patients. Radiotherapy 
TABLE 3. Clinical Trials Combining Immunotherapy and Radiation for Locally Advanced NSCLC
Institution/Group Phase Eligibility Radiotherapy Immunotherapy
Completed
  Chiba Cancer Center III Clinical stage II–IIIA NSCLC 
s/p resection (complete or 
incomplete)
40–60 Gy if residual disease of 
the chest wall, diaphragm, 
pericardium, nodes, or bronchial 
stump
IL-2/LAK cell adoptive immunotherapy 
after two courses of cisplatin/vindesine 
(control arm chemo alone
  Cross Cancer Institute, 
University of Alberta
I Stage IIIB or IV NSCLC Not speciﬁed (delivered to 7/17 pts) L-BLP25 20 mcg or 200 mcg (randomly 
assigned) × 4 doses (weeks 0, 2, 5, and 9)
  Cross Cancer Institute, 
University of Alberta
IIB Stage IIIB or IV NSCLC Not speciﬁed (stage IIIB only) Adjuvant L-BLP25 weekly 1000 μg Sub-Q 
× 8 (Q 6 week maintenance allowed 
starting week 13) vs. best supportive care
  The Cancer Institute 
Hospital of JFCR
I/II Unresectable stage IIIA/B NSCLC 
s/p concurrent or sequential CRT
Thoracic RT ≥50 Adjuvant L-BLP25 sub-Q 1000 μg QW × 8 
→ 1000 μg Q 6 weeks maintenance until 
disease progression
  Multi-institution (START) III Unresectable stage IIIA/B NSCLC 
s/p concurrent or sequential CRT
Thoracic RT ≥50 Adjuvant L-BLP25 sub-Q 806 μg Qweek × 
8→ 806 μg Q 6 weeks maintenance until 
disease progression
Accruing
  Multi-Institution 
(PACIFIC)
III Unresectable stage IIIA/B NSCLC 
s/p concurrent CRT
Thoracic RT, dose unspeciﬁed Adjuvant MEDI4736 × 12 months (dosing 
not available)
  Eastern Cooperative 
Oncology Group  
(ECOG E6508)
II Unresectable stage IIIA/B NSCLC Thoracic RT 66 Gy in 33 fractions 
with concurrent carboplatin/ 
paclitaxel
Adjuvant bevacizumab 15 mg/kg day 1 and 
L-BLP25 806 mcg SQ days 1, 8, and 15 
of cycles 1 and 2, and day 1 of cycles 4, 
6, 8
Terminated
  Multi-Institution 
(START2)
III Unresectable stage IIIA/B NSCLC 
s/p concurrent CRT
Thoracic RT ≥60 Gy in ≥1.8 Gy 
fractions
Adjuvant L-BLP25 sub-Q 806 μg QW × 
8→ 806 μg Q 6 weeks maintenance until 
disease progression
  Multi-Institution 
(INSPIRE)
III Asian pts with stage IIIA/B 
unresectable NSCLC with SD or 
OR following concurrent CRT
Thoracic RT ≥50 Adjuvant L-BLP25 sub-Q 918 μg QW × 
8→ 918 μg Q 6 weeks maintenance until 
disease progression
  Radiation Therapy 
Oncology Group  
(RTOG 9909)
II Completely resected stage II/IIIA 
NSCLC
Thoracic RT 50.4–61.2 Gy in 1.8 Gy 
fractions
Concurrent 11D10 and 3H1 anti-idiotype 
vaccines Sub-Q weekly × 3 weeks → 
monthly × 2 years
NSCLC, non–small-cell lung cancer; Gy, Gray; RT, radiotherapy; IL-2/LAK, interleukin-2/lymphokine activated killer cell; Sub-Q, sub-cutaneous; QW, weekly.
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is typically added only for positive resection margins or 
unexpected upstaging with occult mediastinal involve-
ment. However, SBRT has emerged as the standard of care 
for medically inoperable early stage NSCLC, with local 
control similar to historical surgical results using sublobar 
resection.65,66 The predominant pattern-of-failure for early 
stage NSCLC, whether managed surgically or nonsurgi-
cally, remains distant.67 The adjuvant chemotherapy used 
after surgical resection of high-risk early stage NSCLC is 
rarely used after SBRT as the risk factors that preclude sur-
gery frequently preclude chemotherapy. With distant fail-
ure exceeding 30% at 5 years, novel strategies to improve 
distant control are desperately needed.68 Immunotherapy is 
an appealing partner given the modest and nonoverlapping 
toxicity proﬁle and the potential for SBRT to augment the 
systemic antitumor effects.
Developing Trials and future Directions
No completed or currently accruing prospective studies 
have evaluated radiotherapy–immunotherapy combinations for 
early stage NSCLC. Our group will soon activate a phase I dose 
escalation trial evaluating the PDL-1 inhibitor MPDL3280A in 
combination with SBRT (50 Gy over four to ﬁve fractions) for 
high risk, early stage, medically inoperable NSCLC. Based on 
our preclinical data (unpublished), we postulate that the opti-
mal approach involves priming the immune system with two 
cycles of MPDL3280A followed by concurrent administration 
of MPDL3280A with SAR followed by three cycles of adjuvant 
MPDL3280A. A standard phase one, 3 + 3 design will be used, 
with three dose levels of MPDL3280A (3 mg/kg, 10 mg/kg, and 
1200 mg [equivalent to 15 mg/kg]) with a 15 patient expansion 
cohort at the maximum tolerated dose.
CONCLUSIONS
The impressive efﬁcacy results from recent trials 
evaluating new immunotherapy agents in heavily pretreated, 
metastatic NSCLC have garnered substantial enthusiasm for 
expanding their evaluation to a greater proportion of lung 
cancer patients, including the potential to increase cure rates 
among patients with localized disease. Preclinical data sug-
gest rationale combinatorial strategies with radiotherapy and 
immunotherapy may enhance antitumor effects and improve 
clinical response rates. Hence, multiple clinical trials testing 
immunotherapy–radiotherapy combinations in both meta-
static and localized disease are ongoing or in development. 
Their success will require rationale integration of these two 
modalities based on sound preclinical data, and will need 
to address sequencing, radiation dose fractionation, target 
organ, choice of immunotherapy agent, and patient selection.
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